Leading Us Forward.

Decades of diverse experience & insight.

Aziyo’s executives bring decades of experience in regenerative medicine, biomedical engineering and biologics processing. With their diverse experiences, they provide insight and guidance that equips us to continually innovate our products to best serve patients and their families.

The Leadership Team.

Ron Lloyd

President & CEO

Ron Lloyd joined Aziyo in 2018 as President and Chief Executive Officer. Ron most recently served as Executive Vice President and President of Hospital Therapies for Mallinckrodt Pharmaceuticals where he created an integrated hospital organization, combining entities from previous acquisition with revenues exceeding $1 billion. Prior to Mallinckrodt, Mr. Lloyd was with Baxter Healthcare where he held the positions of President of Immunology, General Manager, BioScience US Region and Vice President, Global Marketing for the BioScience Division.

Read More…

His tenure at Baxter included a leadership role in developing and implementing strategies to build a regenerative medicine business. Before joining Baxter, Ron served in a number of capacities at Abbott Laboratories, including Divisional Vice President, Marketing and Business Development, for the International Division. Mr. Lloyd holds a Master of Science in Industrial Administration from Carnegie Mellon University and a Bachelor of Arts in Management Science from Westminster College, where he was a two-time basketball academic all-American.

Tom Englese

Chief Commercial Officer

Tom Englese joined Aziyo in 2019 as Chief Commercial Officer. Prior to joining Aziyo, Mr. Englese served as Senior Vice President & General Manager of North America Hospital Therapies for Mallinckrodt Pharmaceuticals where he managed a multi-product portfolio with revenues in excess of $1 billion. Prior to Mallinckrodt, he spent several years with Ikaria where held the positions of Vice President Customer Operations & Vice President Contracting & Reimbursement.

Read More…

Before joining Ikaria Mr. Englese held numerous roles with Baxter in the Anesthesia and Critical Care division. Mr. Englese holds a Master of Business Administration in Finance from The Pennsylvania State University and a Bachelor of Science in Marketing and Communications from Villanova University.

Darryl Roberts, Ph.D.

EVP, Operations & Product Development

Darryl Roberts, Ph.D. is Executive Vice President and General Manager of Aziyo’s Musculoskeletal Product division. Previously, from 2013 to 2015, Dr. Roberts was Senior Vice President of Operations at TELA Bio, Inc. where he was responsible for Manufacturing, Quality and Regulatory Affairs. From 2007 to 2013, Dr. Roberts was a member of the senior leadership team at LifeCell Corporation, a publicly traded company that was purchased by Kinetic Concepts, Inc.

Read More…

His prior experience also includes involvement in the development and launch of a variety of pharmaceutical, medical device and consumer products at Johnson & Johnson, including Splenda®, ACUVUE® Brand Contact Lenses and the Cypher® Sirolumus-eluting Stent. He holds Bachelor of Science and Ph.D. degrees in Chemistry from the University of Alabama.

Jerry Riebman, M.D., M.A., FACS, FACC

Chief Medical Officer

Dr. Riebman joined Aziyo in January of 2020 as the Chief Medical Officer. He has previously had numerous leadership roles in industry, most recently at Amgen, where he was responsible for the US Medical strategy and program execution in Heart Failure. Preceding this, he was the Lead Medical Director for US CV Medical at Novartis Pharmaceuticals, and had key responsibilities including the launch of Entresto™, leadership of the Investigator-Initiated Trials program, strategic oversight of the Phase IV evidence generation clinical trials program, and was Medical Lead for the Canakinumab program. 

Read More…

Prior to this, he served as Executive Director of Medical Affairs for Ethicon Biosurgery, a Johnson & Johnson Global Surgery Group. Dr. Riebman is the inventor on over 14 medical device patents and has entrepreneurial and operational expertise in the development and commercialization of novel medical product solutions. He was also the founder and executive leader of several successful medical device and product companies. Prior to industry, Dr. Riebman’s clinical experience includes Cardiovascular and Thoracic Surgery practice in academic and community environments, including heart transplantation and heart assist devices. He completed medical studies at Temple University in Philadelphia, and trained in Internal Medicine at NYMC-Metropolitan Hospital Center, NY. He completed General Surgery training at Temple University, followed by a NHLBI research fellowship in the Artificial Heart Lab at the University of Utah, and a Cardiothoracic & Vascular Surgery residency at McGill University in Montreal. Dr. Riebman was board certified in both General Surgery and Thoracic Surgery, and is a Fellow of the American College of Surgeons and the American College of Cardiology.

Jeff Hamet

V.P. of Finance

Jeff Hamet is Vice President of Finance. Mr. Hamet joined Aziyo Biologics with over 25 years of senior-level finance, accounting and management experience primarily in the life sciences, medical services and high-technology industries. From 2013 through 2015, Mr. Hamet served as President and Chief Financial Officer of NeurExpand Brain Center LLC. From 2004 through 2012, Mr. Hamet was Vice President and Corporate Controller of Martek Biosciences Corporation.

Read More…

During Mr. Hamet’s tenure with Martek, the company experienced dramatic growth in revenues, profits and employees, culminating in its acquisition by Royal DSM N.V. for $1.1 billion. Prior to joining Martek, Mr. Hamet served as a financial executive at IGEN International, Inc. and ARBROS Communications, Inc. Mr. Hamet spent the first nine years of his career at Arthur Andersen LLP, an international public accounting firm. He holds a B.S. in accounting from the University of Maryland and is a Certified Public Accountant.

Courtney Guyer

V.P. of Marketing

Courtney Guyer joined Aziyo in 2018 as Vice President of Marketing bringing global leadership experience in established and start-up medical device companies across multiple therapies. Prior to joining Aziyo, Ms. Guyer served as Senior Director of Marketing at Medinol, an international cardiovascular startup where she led the pivotal launches of both Bare Metal and Drug Eluting Coronary Stent products. Previous to that she led US and Global Marketing teams at LifeCell for seven years working on both upstream and downstream launches and product portfolio projects.

Read More…

In addition, she has held various sales and marketing roles at Johnson & Johnson and Merck. Ms. Guyer holds a Masters of Business Administration degree from The Wharton School at the University of Pennsylvania and a Bachelor of Science in Biology from The Pennsylvania State University.

The Board of Directors.

Kevin Rakin

Chairman

Kevin Rakin is co-founder of HighCape Partners and brings more than 25 years of experience as an executive and investor in the life sciences industry. He most recently served as President of Shire Regenerative Medicine. Prior to joining Shire, Mr. Rakin was Chairman and Chief Executive Officer of Advanced BioHealing from 2007 until its acquisition by Shire in 2011 for $750M. Before that, he served as an executive-in-residence at Canaan Partners.

Read More…

Previously, he was a Co-Founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, Inc., a publicly traded pharmacogenomics company, until its merger with Clinical Data, Inc. in 2005. His Board memberships include Cheetah Medical, Inc. (Chairman), Cybrexa, Inc., and TELA Bio, Inc., as well as Histogenics Corp. and Collagen Matrix, Inc.

He has previously served as a Board member for Ipsogen SA, OMRIX Biopharmaceuticals, Inc., and Clinical Data, Inc. Mr. Rakin received an M.B.A. from Columbia University and B.Com and B.Com (Hons) degrees from the University of Cape Town.

Matt Zuga

Board Member

Since October 2013, Mr. Zuga has been a co-founder and partner of HighCape, and he brings more than 25 years of life sciences investment and banking experience. From August 2012 to September 2013, Mr. Zuga was a managing director of Syngenta Ventures Pte Ltd, an investment vehicle of Syngenta Corp. He was also the founder and managing member of Red Abbey, an investment company, from January 2004 to August 2012. 

Read More…

Prior to Red Abbey, Mr. Zuga was a managing director and the head of life sciences investment banking at Legg Mason from 1999 to 2003. He is currently on the boards of Aziyo Biologics, Inc., AgriMetis, LLC, Alba Therapeutics Corporation, MF Fire, Inc. and Virtue Labs LLC. Mr. Zuga received an MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and a B.S. in Business Administration/Finance from Ohio State University.

Maybelle Jordan

Board Member

Ms. Jordan has served as Vice President of Business Development of Biomerix Corporation, a biomaterials company focused on scaffold technology in the medical technology industry, since 2011, and as Chief Operating Officer for Biomerix from 2003 to 2011. Ms. Jordan also co-founded and served as President and CEO of MTrap Inc., a clinical-stage biomaterials company developing a cancer therapeutic device for treatment of advanced ovarian cancer, from 2015 to 2019. Ms. Jordan holds an M.B.A. from Harvard University and a B.S. in Biology from Yale University.

Randy Mills, Ph.D.

Board Member

Dr. Randy Mills brings over 25 years of healthcare leadership as both an executive and inventor. As CEO of the Sanford Burnham Prebys Medical Discovery Institute, he oversees a multidisciplinary campus that includes a cancer research center and graduate school. Previously, as CEO of Be The Match, he launched a plan to democratize Cell Therapy, resulting in significantly more bone marrow matches for ethnically diverse patients. 

Read More…

Prior to that, as President of the California Institute for Regenerative Medicine, he improved the speed and transparency of the agency. Randy has led significant growth in both private and publicly traded companies. As CEO of Osiris Therapeutics, he commercialized five cell therapy products and led the company through an IPO. Starting out, the subject of his graduate research, BioCleanse, became the core technology that launched Regeneration Technologies.

Brigid A. Makes

Board Member

Ms. Makes has served as an independent consultant for medical device and healthcare companies since July 2017, specifically advising on finance, accounting and funding responsibilities. From September 2011 to July 2017, Ms. Makes served as Senior Vice President and Chief Financial Officer of Miramar Labs, Inc., a 138 biotechnology company focused on aesthetics and dermatology. 

Read More…

From 2006 to 2011, Ms. Makes served as Senior Vice President and Chief Financial Officer of AGA Medical Corp, a medical device company developing interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders. Prior to joining AGA, Ms. Makes held various positions at Nektar Therapeutics Inc. from 1999 to 2006, including serving as Chief Financial Officer. Since December 2019, Ms. Makes has also been a member of the board of directors of Mind Medicine (MindMed) Inc., a publicly traded neuro-pharmaceutical company, where Ms. Makes serves on the Audit Committee, the Compensation Committee and the Nominating/Governance Committee. Ms. Makes holds an M.B.A. from Bentley University and a Bachelor of Commerce degree in Finance & International Business from McGill University.

Ron Lloyd

President & CEO

Ron Lloyd joined Aziyo in 2018 as President and Chief Executive Officer. Ron most recently served as Executive Vice President and President of Hospital Therapies for Mallinckrodt Pharmaceuticals where he created an integrated hospital organization, combining entities from previous acquisition with revenues exceeding $1 billion. Prior to Mallinckrodt, Mr. Lloyd was with Baxter Healthcare where he held the positions of President of Immunology, General Manager, BioScience US Region and Vice President, Global Marketing for the BioScience Division.

Read More…

His tenure at Baxter included a leadership role in developing and implementing strategies to build a regenerative medicine business. Before joining Baxter, Ron served in a number of capacities at Abbott Laboratories, including Divisional Vice President, Marketing and Business Development, for the International Division. Mr. Lloyd holds a Master of Science in Industrial Administration from Carnegie Mellon University and a Bachelor of Arts in Management Science from Westminster College, where he was a two-time basketball academic all-American.

Want to Receive Updates About Upcoming Webinars?

Click below to join our webinar mailing list.

External links are provided for informational purposes only.
 
Aziyo bears no responsibility for the accuracy, legality or content of the external site or for that of subsequent links.
CANCEL     CONTINUE